New copycat cancer drug enters human testing
NCT ID NCT06551064
Summary
This study is testing a new, similar version of the cancer drug Keytruda (called FYB206) to see if it behaves the same way in the body. It involves patients with stage IIB/IIC or III melanoma who have had their cancer completely removed by surgery. The main goal is to check if the new drug's levels in the blood over time are equivalent to the original Keytruda.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Formycon Investigative Site
Sarajevo, Bosnia and Herzegovina
-
Formycon Investigative Site
Sofia, Bulgaria
-
Formycon Investigative Site
Tartu, Estonia
-
Formycon Investigative Site
Batumi, Georgia
-
Formycon Investigative Site
Kutaisi, Georgia
-
Formycon Investigative Site
Tbilisi, Georgia
-
Formycon Investigative Site
Kaunas, Lithuania
-
Formycon Investigative Site
Chisinau, Moldova
-
Formycon Investigative Site
Skopje, North Macedonia
-
Formycon Investigative Site
Krakow, Poland
-
Formycon Investigative Site
Lodz, Poland
-
Formycon Investigative Site
Bucharest, Romania
-
Formycon Investigative Site
Cluj-Napoca, Romania
-
Formycon Investigative Site
Belgrade, Serbia
-
Formycon Investigative Site
Kragujevac, Serbia
-
Formycon Investigative Site
Niš, Serbia
-
Formycon Investigative Site
Kyiv, Ukraine
Conditions
Explore the condition pages connected to this study.